Breast Cancer: Drugs
2026-07-06 · Department of Health and Social Care · HL1761 · Official question
Baroness Ritchie of Downpatrick
Question
To ask His Majesty's Government what estimate they have made of the number of patients who would have otherwise benefited from the HER2-low metastatic breast cancer drug Enhertu since it was rejected for use on the NHS in England in 2024.
Answer
HER2‑low breast cancer is managed with treatments for HER2‑negative breast cancer. The National Institute for Health and Care Excellence (NICE) has published guidance recommending a number of medicines for the treatment of HER2-negative breast cancer whic...